

Special Issue

Tumor-Promoting Functions of DNA Damage and Stress Response Signaling

Message from the Guest Editors

Therapies with broad targeting anticancer activity have significant favorable effects. Nevertheless, the presence of resistant cancer cells or acquisition of resistance in response to drug treatment represent major barriers to a full cure. Activation of DNA damage response (DDR) remains the main route for efficient cancer treatment in response to chemo- and radiotherapy. It is well documented, however, that under certain conditions, DDR can promote tumorigenesis. This Special Issue will highlight the emerging role of DNA damage and stress responses as important drivers of cancer evolution at the level of epigenetic reprogramming, modulation of senescence, induction of cancer cell plasticity, regulation of immune responses and tumor microenvironment, as well as other non-genetic changes. These novel basic and translational aspects could advance our understanding of targeting DNA damage and stress responses, ultimately improving our current anticancer therapeutic regimes.

Guest Editors

Dr. Dmitry V. Bulavin

Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM, Université Côte d'Azur, CNRS, Nice, France

Dr. Alexander Emelyanov

Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM, Université Côte d'Azur, CNRS, Nice, France

Deadline for manuscript submissions

closed (31 January 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/69056

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)